Biotechnology

Ocean Biomedical, Inc.

Ocean Biomedical, Inc. released FY2025 Q1 earnings on May 15, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.0905

Ocean Biomedical Inc. Submits FY 2024 10-K Annual Report Amendment

Ocean Biomedical, Inc. released FY2024 Q4 earnings on April 8, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0.0102 (forecast USD -0.24)

Ocean Biomedical, Inc. released FY2024 annual earnings on April 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3446 (forecast USD -0.89)

Ocean Biomedical Receives Patent Approval for New Bispecific Antibody from CNIPA

Ocean Biomedical Achieves Breakthrough in EGFR-Mutant Lung Cancer and Plans to Engage with FDA

Ocean Biomedical Receives NIH Funding to Advance Malaria Vaccine Research

Ocean Biomedical, Inc. released FY2024 9 Months Earnings on January 13 (EST) with actual revenue of 0 USD and EPS of -0.3527 USD

Ocean Biomedical, Inc. released FY2024 Q3 earnings on January 13 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2011 USD (forecast -0.23 USD)

Ocean Biomedical, Inc. released FY2024 Q2 earnings on December 23 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.6269 USD (forecast -0.22 USD)

Ocean Biomedical, Inc. released FY2024 Semi-Annual Earnings on December 23 (EST) with actual revenue of 0 USD and EPS of -0.1544 USD

Ocean Biomedical, Inc. released FY2024 Q1 earnings on December 23 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS 0.4753 USD (forecast -0.2 USD)

Ocean Biomedical, Inc. released FY2023 Q4 earnings on November 25 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.619 USD (forecast -0.19 USD)

Ocean Biomedical, Inc. released FY2023 annual earnings on November 25, 2024 (EST), with actual revenue of 0 USD (forecast 0 USD) and actual EPS of -4.3535 USD (forecast -3.08 USD)

Ocean Biomedical Announces Key Patent for Malaria Treatment

Ocean Biomedical, Inc. Receives Notification from NASDAQ

Ocean Biomedical, Inc. Receives Notice from NASDAQ Regarding Delay in Submitting 10-Q Quarterly Report

Ocean Biomedical Company Obtains Patent License for Malaria Antibodies

Ocean Biomedical, Inc. released FY2022 Q4 earnings on March 31, 2023 (EST), with actual revenue of 0 and EPS of -0.042 (forecast EPS was -0.16)

Ocean Biomedical, Inc. released FY2022 Annual Earnings on March 31 (EST), actual revenue 0 (forecast 0), actual EPS -0.7432 (forecast -0.66)

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap